Oligonucleotide Therapeutics First Annual Meetingof the Oligonucleotide Therapeutics Society, Volume 1082

This volume concentrates on the most relevant oligonucleotide research and drug development areas and emphasizes the basic mechanisms and biology of oligonucleotide reagents.Chapters are devoted to RNAi, oligonucleotide delivery, and immunomodulation. Because of the advanced stages of oligonucleotide-based drug development, preclinical and clinical data are also presented by leaders in the field.NOTE: Annals volumes are available for sale as individual books or as a journal. For information on institutional journal subscriptions, please visit www.blackwellpublishing.com/nyas.ACADEMY MEMBERS: Please contact the New York Academy of Sciences directly to place your order (www.nyas.org). Members of the New York Academy of Science receive full-text access to the Annals online and discounts on print volumes. Please visit www.nyas.org/membership/main.asp for more information about becoming a member.

Thomas Tuschl is a German biochemist and molecular biologist, known for his research on RNA. John J. Rossi is the editor of Oligonucleotide Therapeutics: First Annual Meetingof the Oligonucleotide Therapeutics Society, Volume 1082, published by Wiley.